DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
Clinical Trials for Brevibloc Double Strength In Plastic Container
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT01114971 | Labetalol and Esmolol: Vital Signs and Post Operative Pain Management | Recruiting | Cedars-Sinai Medical Center | Phase 4 | This study proposes to investigate the effects of labetalol or esmolol on managing the vital signs (like blood pressure and heart rate) during surgery, on pain management, and on the later recovery after surgery. It will also assess the cost-effectiveness of Labetalol and esmolol for outpatient surgery. |
NCT01179113 | Esmolol Infusion During Laminectomy: Effect on Quality of Recovery | Terminated | Cedars-Sinai Medical Center | Phase 4 | The purpose of this study is to evaluate the effects of esmolol, a drug which is commonly administered during surgery to help control blood pressure and heart rate, on postoperative pain levels and requirements for pain medication. |
NCT01208402 | Esmolol for Treatment of Perioperative Tachycardia | Terminated | Baxter Healthcare Corporation | Phase 3 | The purpose of this study is to find out if Esmolol is a safe and effective alternative treatment compared to standard treatment using a long acting beta blocker drug, in controlling abnormal heart rate before, during and immediately after surgery. |
NCT01208402 | Esmolol for Treatment of Perioperative Tachycardia | Terminated | Duke University | Phase 3 | The purpose of this study is to find out if Esmolol is a safe and effective alternative treatment compared to standard treatment using a long acting beta blocker drug, in controlling abnormal heart rate before, during and immediately after surgery. |
NCT01232400 | Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage | Withdrawn | University of Michigan | N/A | The purpose of this study is to evaluate the clinical effect of esmolol treatment on cardiac function and electrophysiology; to assess the effects of esmolol treatment on serum adrenergic and cardiac biomarkers; to explore the safety of esmolol treatment shortly after subarachnoid hemorrhage (SAH). Patients will be followed for a maximum of 1 month after the index SAH. The primary outcome will be change in systolic function - ejection fraction by Simpson's rule (baseline versus Day 7 +/- 2 after SAH). |
Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Brevibloc Double Strength In Plastic Container
Condition Name
Condition Name for Brevibloc Double Strength In Plastic Container | |
Intervention | Trials |
Septic Shock | 2 |
Hypertension | 1 |
Overdose of Beta-adrenergic Blocking Drug | 1 |
High-risk, Non-cardiovascular Surgeries | 1 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Export unavailable in trial.
Subscribe for complete access.
Condition MeSH
Clinical Trial Locations for Brevibloc Double Strength In Plastic Container
Trials by Country
Clinical Trial Progress for Brevibloc Double Strength In Plastic Container
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Brevibloc Double Strength In Plastic Container
Sponsor Name